"Interferon Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).
| Descriptor ID |
D007370
|
| MeSH Number(s) |
D12.644.276.374.440.890 D12.776.467.374.440.890 D23.529.374.440.890
|
| Concept/Terms |
Interferon Type I- Interferon Type I
- Type I Interferons
- Interferons, Type I
- Interferons Type I
- Type I Interferon
- Interferon, Type I
|
Below are MeSH descriptors whose meaning is more general than "Interferon Type I".
Below are MeSH descriptors whose meaning is more specific than "Interferon Type I".
This graph shows the total number of publications written about "Interferon Type I" by people in this website by year, and whether "Interferon Type I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 2 | 0 | 2 |
| 2005 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 4 | 1 | 5 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 0 | 3 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 3 | 2 | 5 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 4 | 5 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 2 | 3 |
| 2022 | 3 | 0 | 3 |
| 2023 | 4 | 1 | 5 |
| 2024 | 1 | 1 | 2 |
| 2025 | 2 | 2 | 4 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon Type I" by people in Profiles.
-
Brain endothelial cells orchestrate a neuroprotective antiviral state in the CNS in response to peripheral viral pattern sensing. Immunity. 2026 Jul 14; 59(7):1825-1842.e11.
-
Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. Nat Commun. 2026 06 15; 17(1).
-
Variability in the TLR3 type I interferon pathway is predictive of RNA vaccine responses. Sci Adv. 2026 May 15; 12(20):eaed8930.
-
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025 11; 647(8089):488-497.
-
IRG1 catalyzed energy metabolite itaconic acid restrains type I interferon-dependent immune responses by alkylation of TBK1. Cell Rep. 2025 Oct 28; 44(10):116336.
-
Type I interferon limits central nervous system autoimmunity by modulating the microRNA-21-FOXO1 axis in pathogenic T helper 17 cells. Sci Transl Med. 2025 09 10; 17(815):eadp5802.
-
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature. 2025 10; 646(8084):462-473.
-
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity. Nat Cancer. 2024 04; 5(4):601-624.
-
Type I interferons, inflammation, and fatigue in a longitudinal RNA study of women with breast cancer. Brain Behav Immun. 2024 May; 118:312-317.
-
Blockade of interferon signaling decreases gut barrier integrity and promotes severe West Nile virus disease. Nat Commun. 2023 09 25; 14(1):5973.